Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

84.24 -0.45 (-0.53%)
Streaming Delayed Price Updated: 3:51 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023
Via Benzinga
US Stocks Mixed; SAIC Posts Upbeat Results
U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares... 
Via Benzinga
FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients
The U.S. 
Via Benzinga
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
This Biotech Could Soon Go Parabolic, But Should You Buy It?
Its situation is neither as good nor as bad as it might seem at first glance. 
Via The Motley Fool
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for  
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
16 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Preview For Blueprint Medicines
Via Benzinga
FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16... 
Via Benzinga
9 Analysts Have This to Say About Blueprint Medicines
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: 
Via Benzinga
Recap: Blueprint Medicines Q3 Earnings
Blueprint Medicines (NASDAQ:BPMC) reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday
Needham raised Uber Technologies, Inc. (NYSE: UBER) price target from $52 to $54. Needham analyst Bernie McTernan maintained the stock with a Buy rating. Uber shares fell 0.3% to $29.65 in pre-market... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.